Kopran Limited has informed the Exchange about Investor Presentation
KOPRAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kopran Limited reported its Q4 FY2025-26 results showing strong sequential improvement with quarterly revenue of Rs. 23,402 lakhs (up 36% YoY) and EBITDA of Rs. 4,057 lakhs, marking the highest ever quarterly revenue and EBITDA. Q4 EBITDA margin expanded significantly to 17.34% from 8.12% in Q4 FY2024-25. For the full year FY2025-26, revenue stood at Rs. 68,142 lakhs with EBITDA of Rs. 7,790 lakhs and net profit of Rs. 2,573 lakhs. Despite operational improvements, net profit declined YoY from Rs. 3,855 lakhs due to forex losses of Rs. 1,595 lakhs for the year. The company is an integrated pharma player with API and Formulations verticals, exporting to 50+ nations. A key development is the proposed amalgamation of subsidiary Kopran Laboratories Limited into Kopran Limited, with NCLT having admitted the application on April 9, 2026 and shareholder meeting scheduled for June 3, 2026.
The strong Q4 performance with margin expansion signals operational improvements, though the full-year profit decline due to forex losses may weigh on investor sentiment. The pending amalgamation could consolidate operations and improve efficiency.